Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.50 |
| ▸ | CA2 | P00918 | 18/20 | 0.50 |
| ▸ | CA9 | Q16790 | 17/20 | 0.50 |
| ▸ | CA4 | P22748 | 12/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078575 | 0.83 | LIPG (0.54) | LIPGKMT2A | |
| SCHEMBL6077310 | 0.83 | LIPG (0.56) | LIPGMEN1KMT2A | |
| SCHEMBL6077604 | 0.82 | LIPG (0.57) | LIPGMEN1KMT2A | |
| SCHEMBL6078875 | 0.79 | LIPG (0.45) | LIPGMEN1KMT2A | |
| SCHEMBL15918237 | 0.76 | LIPG (0.78) | LIPG | |
| SCHEMBL6079147 | 0.75 | LIPG (0.54) | LIPG | |
| SCHEMBL14846552 | 0.75 | LIPG (0.58) | CA1CA2CA9CA7CA12 | |
| SCHEMBL6077439 | 0.72 | LIPG (0.35) | LIPG | |
| SCHEMBL6077032 | 0.70 | PARP1 (0.38) | LIPG | |
| SCHEMBL6076712 | 0.69 | L3MBTL1 (0.38) | LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | CA1 4825/4885CA2 4572/4885CA9 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.